Gretchen von Allmen, MD
Neurology with Special Qualifications in Child Neurology · Houston, TXNPI 1801976154
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $27,094 of the $30,788 with a category attached, or 88.0%. Greenwich Biosciences, Inc. accounts for 91.2% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2019 at $16,961 and has fallen 98.5% since, to $250 in 2025. Among neurology with special qualifications in child neurology clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 94 payments — averaging $327.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Greenwich Biosciences, Inc.$28K
- Neuropace, Inc.$2K
- UCB, Inc.$439
- Jazz Pharmaceuticals Inc.$219
- Livanova USA, Inc.$205
- SK Life Science, Inc.$121
- plus $115 from 6 others
Across 8 payments — averaging $29,936 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Livanova USA, Inc.$238K
- Neuropace, Inc.$2K
What the payments were for
- Consulting fees$5002%
- Speaking & faculty fees$27,09488%
- Food & beverage$3,19510%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Greenwich Biosciences, Inc. | 32 | $28,083 |
| Neuropace, Inc. | 35 | $1,607 |
| UCB, Inc. | 13 | $439 |
| Jazz Pharmaceuticals Inc. | 2 | $219 |
| Livanova USA, Inc. | 4 | $205 |
| SK Life Science, Inc. | 2 | $121 |
| Upsher-smith Laboratories LLC | 1 | $30 |
| Acadia Pharmaceuticals Inc | 1 | $24 |
| Otter Pharmaceuticals, LLC | 1 | $23 |
| Aquestive Therapeutics, Inc. | 1 | $17 |
| Mallinckrodt Enterprises LLC | 1 | $14 |
| Aucta Pharmaceuticals, Inc. | 1 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$30,788 in reported general payments places this provider in the 90th percentile of 193 neurology with special qualifications in child neurology providers in Texas.
See all neurology with special qualifications in child neurology providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other neurology with special qualifications in child neurology in Houston
- Huda ZoghbiHouston$5.5M
- Shade MoodyHouston$194K
- Mary Kay KoenigHouston$171K
- Victoria HardwickHouston$10K
- Joshua RotenbergHouston$9K
- Mered ParnesHouston$5K
- Sarah WilsonHouston$5K
- Roy EltermanDallas$5.9M
- Diana CastroDenton$343K
- Michael PerryFort Worth$162K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.